FDA ready to bless mixing and matching of COVID-19 vaccines as boosters: reportnews2021-10-19T13:49:55+00:00October 19th, 2021|Fierce Pharma|
FDA missing more approval target dates as COVID slows inspectionsnews2021-10-19T12:47:07+00:00October 19th, 2021|Fierce Pharma|
Oyster Point, with AbbVie and Novartis in its sights, wins first FDA approval for nasal spray to treat dry eye diseasenews2021-10-19T09:54:38+00:00October 19th, 2021|Fierce Pharma|
Corium, bouncing back from FDA rejection, snags PDUFA date for weekly Alzheimer’s patchnews2021-10-19T08:58:28+00:00October 19th, 2021|Fierce Pharma|
Roche lands approval to slash Gazyvaro infusion time in EU, bringing treatment in line with MabTheranews2021-10-19T08:54:20+00:00October 19th, 2021|Fierce Pharma|
Russian team gets green light to trial nasal COVID-19 vaccine but lacks funding to start studynews2021-10-19T08:50:31+00:00October 19th, 2021|Fierce Pharma|
Boehringer’s interchangeable tag for Humira biosim is a ‘landmark’ win for the field: analystnews2021-10-18T19:39:05+00:00October 18th, 2021|Fierce Pharma|
Regeneron, Novo Nordisk, Lilly and AbbVie stake claims on September’s list of top TV ad spendersnews2021-10-18T17:52:25+00:00October 18th, 2021|Fierce Pharma|
FDA delays decision on Moderna’s COVID-19 vaccine in 12-17 age group because of myocarditis concerns: WSJnews2021-10-18T15:23:00+00:00October 18th, 2021|Fierce Pharma|
Pandemic launch woes: Esperion cuts 40% of workforce, goes all in on cholesterol drug’s outcomes trialnews2021-10-18T14:35:41+00:00October 18th, 2021|Fierce Pharma|
